PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31387809-0	2019	Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib.	Sorafenib	72-81	interleukin 6	Homo sapiens	10-14	
31387809-3	2019	Therefore, in the present study, we attempted to investigate the effect and mechanisms of IL-6 on sensitivity of HCC cells to sorafenib regarding the cell proliferation and apoptosis.	Sorafenib	126-135	interleukin 6	Homo sapiens	90-94	
31387809-7	2019	Furthermore, sorafenib significantly inhibited cell proliferation, IL-6 level and activation of p-PI3K/AKT while promoted the cell apoptosis rate and Caspase3 level compared as the control group, which were further promoted by administration of si IL-6.	Sorafenib	13-22	interleukin 6	Homo sapiens	67-71	
31387809-7	2019	Furthermore, sorafenib significantly inhibited cell proliferation, IL-6 level and activation of p-PI3K/AKT while promoted the cell apoptosis rate and Caspase3 level compared as the control group, which were further promoted by administration of si IL-6.	Sorafenib	13-22	interleukin 6	Homo sapiens	248-252	
31387809-8	2019	Therefore, downregulating IL-6 could be a potential treatment to increase the cell sensitivity of HCC cells to sorafenib.	Sorafenib	111-120	interleukin 6	Homo sapiens	26-30